# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target ...
Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.60) per share which met the analyst consensus estimate.
HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 ...
The trial will also evaluate the effects of apitegromab on the durability of weight loss upon withdrawal of GLP-1 RA therapy. T...
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target ...
HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 ...
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patientsAnalysis of ba...
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/...